PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data.
María José Jiménez-Santos, Alba Nogueira-Rodríguez, Elena Piñeiro-Yáñez, Hugo López-Fernández, Santiago García-Martín, Paula Gómez-Plana, Miguel Reboiro-Jato, Gonzalo Gómez-López, Daniel Glez-Peña, Fátima Al-Shahrour
Author Information
María José Jiménez-Santos: Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
Alba Nogueira-Rodríguez: CINBIO, Universidade de Vigo, Department of Computer Science, ESEI-Escuela Superior de Ingeniería Informática, 32004 Ourense, Spain.
Elena Piñeiro-Yáñez: Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
Hugo López-Fernández: CINBIO, Universidade de Vigo, Department of Computer Science, ESEI-Escuela Superior de Ingeniería Informática, 32004 Ourense, Spain.
Santiago García-Martín: Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
Paula Gómez-Plana: Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
Miguel Reboiro-Jato: CINBIO, Universidade de Vigo, Department of Computer Science, ESEI-Escuela Superior de Ingeniería Informática, 32004 Ourense, Spain.
Gonzalo Gómez-López: Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. ORCID
Daniel Glez-Peña: CINBIO, Universidade de Vigo, Department of Computer Science, ESEI-Escuela Superior de Ingeniería Informática, 32004 Ourense, Spain. ORCID
Fátima Al-Shahrour: Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. ORCID
Genomics studies routinely confront researchers with long lists of tumor alterations detected in patients. Such lists are difficult to interpret since only a minority of the alterations are relevant biomarkers for diagnosis and for designing therapeutic strategies. PanDrugs is a methodology that facilitates the interpretation of tumor molecular alterations and guides the selection of personalized treatments. To do so, PanDrugs scores gene actionability and drug feasibility to provide a prioritized evidence-based list of drugs. Here, we introduce PanDrugs2, a major upgrade of PanDrugs that, in addition to somatic variant analysis, supports a new integrated multi-omics analysis which simultaneously combines somatic and germline variants, copy number variation and gene expression data. Moreover, PanDrugs2 now considers cancer genetic dependencies to extend tumor vulnerabilities providing therapeutic options for untargetable genes. Importantly, a novel intuitive report to support clinical decision-making is generated. PanDrugs database has been updated, integrating 23 primary sources that support >74K drug-gene associations obtained from 4642 genes and 14 659 unique compounds. The database has also been reimplemented to allow semi-automatic updates to facilitate maintenance and release of future versions. PanDrugs2 does not require login and is freely available at https://www.pandrugs.org/.
References
Cell Rep. 2022 Feb 22;38(8):110400
[PMID: 35196490]
